We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D Dose Finding Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01092338
Recruitment Status : Completed
First Posted : March 24, 2010
Results First Posted : September 18, 2013
Last Update Posted : September 18, 2013
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Children's Hospital of Philadelphia

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
AIDS
Intervention: Drug: Cholecalciferol (Vit D3)

  Participant Flow


  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
4000IU/d of Vitamin D3 No text entered.
7000IU/d Vitamin D3 No text entered.
Total Total of all reporting groups

Baseline Measures
   4000IU/d of Vitamin D3   7000IU/d Vitamin D3   Total 
Overall Participants Analyzed 
[Units: Participants]
 22   22   44 
Age 
[Units: Participants]
     
<=18 years   9   7   16 
Between 18 and 65 years   13   15   28 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 18.4  (4.5)   19.1  (5.0)   18.7  (4.7) 
Gender 
[Units: Participants]
     
Female   7   7   14 
Male   15   15   30 
Region of Enrollment 
[Units: Participants]
     
United States   22   22   44 


  Outcome Measures

1.  Primary:   Safety   [ Time Frame: 12 weeks ]

2.  Primary:   Efficacy of the Two Doses (4000 and 7000 IU/d)   [ Time Frame: 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information